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Lactobacillus for Gastroenteritis in Children
To the Editor: Schnadower et al. (Nov. 22 issue)1 
report that preschool children with acute gastro-
enteritis who received a 5-day course of Lactobacil-
lus rhamnosus GG did not have better outcomes 
than those who received placebo. The authors 
did not highlight a crucial limitation of the trial: 
stool samples were obtained from 78.4% of the 
participants, with 45.6% of these samples posi-
tive for viruses. A therapeutic benefit of probiot-
ics has been documented mostly in acute gastro-
enteritis of a viral origin.2,3
Furthermore, probiotics are more effective 
when administered early in the course of diar-
rhea rather than later,2,3 whereas in most par-
ticipants in this trial, therapy was initiated on 
the third or fourth day of diarrhea. Finally, some 
of the participants received antibiotics, although 
many strains of lactobacilli are susceptible to 
antimicrobial agents.4 Moreover, after antibiotic 
therapy, probiotics induced a markedly delayed 
and incomplete reconstitution of the intestinal 
mucosal microbiome.5
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To the Editor: Schnadower et al. found that 
L. rhamnosus GG was ineffective in acute gastro-
enteritis in children. They provided several expla-
nations for their negative results, which contrast-
ed with available data supporting the use of 
L. rhamnosus GG in children.1,2
Unfortunately, the authors did not report im-
portant weaknesses of their trial. For example, 
data show that probiotics should ideally be initi-
ated early in the course of gastroenteritis.3,4 In 
this trial, the median duration of diarrhea be-
fore treatment was 53.2 hours (range, 29.0 to 
81.3). This delay seems too long for a disease 
that typically lasts less than 7 days. With such a 
delay in the beginning of treatment, it is hard to 
show a difference in the duration of diarrhea. In 
addition, with the use of a primary outcome 
based on a score of 9 or higher on the Vesikari 
scale (scores range from 0 to 20, with higher 
scores indicating more severe disease), which 
was determined at any time point during the 14-
day follow-up period after enrollment, it is hard 
to determine the effect of L. rhamnosus GG on the 
duration and severity of gastroenteritis. Previous 
studies used the total duration of diarrhea (in 
hours) as the primary outcome. To provide solid 
guidance on the use of probiotics in acute gas-
troenteritis, it would be important to perform a 
large trial to confirm previous data from small-
er studies. However, to confirm the results of 
previous trials, it would be better to adopt the 
same trial design and clinical outcomes. Other-
wise, there is a risk that “bigger” will not be-
come “better.”
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To the Editor: A Cochrane systematic review1 
concluded that the use of specific probiotics 
along with rehydration therapy has beneficial ef-
fects in reducing the duration and stool frequency 
of acute infectious diarrhea. Cochrane experts ac-
knowledged variability among studies and stated 
that research is needed to guide the use of particu-
lar probiotic regimens in specific patient groups.
The results of the trial by Schnadower et al. 
and those of the trial by Freedman et al., which 
were published in the same issue of the Journal,2 
should be interpreted with caution because of the 
late use of probiotic therapy and the unverified 
viability of strains in liquid suspension in both 
trials. Most children had mild gastroenteritis and 
were recruited after they had had diarrhea for 
2 days. Guidelines recommend probiotic use with-
in the first 24 to 48 hours after symptom onset in 
order to be effective.3 Infectious gastroenteritis in 
Western societies is typically mild and self-limit-
ing, and the use of probiotics may not be criti-
cal.4 This is not the same in less developed areas. 
It would be advisable to perform a subanalysis 
focusing only on severe cases of diarrhea treated 
with reliable probiotic dosing within the first 48 
hours after the onset of symptoms in order to prop-
erly assess the effectiveness of the intervention.
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Dr. Schnadower and colleagues reply: All 
three letters express the oft-stated belief that the 
sooner probiotics are initiated in acute gastroen-
teritis, the greater the effect. However, the refer-
ences cited in these letters do not provide spe-
cific data supporting this contention. The only 
relevant data we found for the use of L. rhamnosus 
GG for the treatment of acute gastroenteritis in a 
population similar to ours showed a nonsignifi-
cant benefit in patients with symptoms lasting 
more than 48 hours.1 We stratified participants 
according to the duration of symptoms (<48 hours 
vs. ≥48 hours) and identified no significant dif-
ferences according to the time of initiation of the 
probiotic (Fig. S1 in the Supplementary Appen-
dix, available with the full text of our article at 
NEJM.org).
Weizman contends that the inclusion of par-
ticipants who were receiving antibiotics was a 
weakness of the trial and that viruses were de-
tected in stool samples obtained from fewer than 
half the participants. We chose to include par-
ticipants who were receiving antibiotics because 
probiotics are often used (with limited evidence) 
to prevent antibiotic-associated diarrhea, treat it, 
or both. No bona fide enteric pathogens are de-
tected in stool samples obtained from many pa-
tients with acute gastroenteritis in North America, 
even with the use of multiplex polymerase-chain-
reaction assays containing more viral targets than 
the one we used and in populations with sparse 
rotavirus vaccine penetration.2 Figure S1 in the 
Supplementary Appendix of our article addressed 
antibiotic use and a viral cause of diarrhea as 
possible determinants of the efficacy of probiot-
ics, and we found no such influences.
Berni Canani questions the use of a total 
score of 9 or higher on the modified Vesikari 
scale as our primary outcome instead of the 
duration of diarrhea. We prefer the Vesikari scale 
score because it includes multiple aspects of 
gastroenteritis severity and we think it better 
reflects the burden of the disease in our popula-
tion.3 However, we also addressed the duration of 
diarrhea as a secondary outcome, and we found 
no difference between the treatment group and 
the placebo group (Table 3 of our article).
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITA DEGLI STUDI DI NAPOLI FEDERICO II on May 16, 2019. For personal use only. No other uses without permission. 
 Copyright © 2019 Massachusetts Medical Society. All rights reserved. 
Correspondence
n engl j med 380;19 nejm.org May 9, 2019 e36(3)
Alvarez-Calatayud et al. express concern that 
viability was lost because the probiotics were 
suspended in a liquid form. Because most young 
participants cannot swallow capsules, we sprin-
kled the contents of each capsule in 20 ml of 
liquid at the time of administration; this com-
mon practice was recommended by the manu-
facturer. We independently tested all batches of 
L. rhamnosus GG at regular intervals to ensure 
purity and viability. Alvarez-Calatayud et al. state 
that probiotics may be less effective in Western 
societies, where gastroenteritis is usually mild; 
this statement contradicts the findings reported 
in one of their references.4 We agree that the 
burden of gastroenteritis is greater in less devel-
oped areas. However, we will not know whether 
L. rhamnosus GG or probiotics improve patients’ 
outcomes in such environments until rigorous 
studies are conducted in those settings.
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Dr. Freedman and colleagues reply: Alvarez-
Calatayud et al. cite a review1 that is prone to the 
same limitations as all systematic reviews,2 and 
the outcomes of ensuing large, randomized, con-
trolled trials are poorly predicted by such re-
views.3 Studies reporting positive results are 
more often published than those that report 
negative results4; this leads subsequent system-
atic reviews2 to overestimate the treatment effect 
size. Although we limited eligibility in our trial 
to participants who had had symptoms for less 
than 72 hours, only 17% of our trial population 
presented within 24 hours after symptom onset, 
and 53% presented within 48 hours after symp-
tom onset. In these subgroups, the respective 
odds ratios for the development of moderate-to-
severe disease among participants who received 
probiotics were 1.05 (95% confidence interval 
[CI], 0.47 to 2.33) and 1.20 (95% CI, 0.79 to 1.83).
Evidence of the viability of the probiotic 
strain in liquid preparations has been published5 
and is available from the manufacturer, which 
also confirmed colony-forming unit counts for 
all trial batches at the end of the shelf life. The 
disease severity effect was assessed by evaluat-
ing the interaction between the treatment and 
the baseline Vesikari scale score, and it was not 
significant (P = 0.86). We performed subgroup 
analyses involving children who presented less 
than 48 hours after symptom onset with varying 
degrees of baseline severity. An analysis involv-
ing 134 children who had a baseline Vesikari 
scale score of 11 or higher yielded an odds ratio 
for moderate-to-severe gastroenteritis of 1.26 
(95% CI, 0.61 to 2.61), whereas the analysis in-
volving 256 children with a Vesikari scale score 
of 9 or less yielded an odds ratio of 0.89 (95% 
CI, 0.48 to 1.66).
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